Adding lenalidomide to GCB-DLBCL cell line (OCI-Ly1) suspensions or the patient-derived mouse xenograft model (CY-DLBCL), both resistant to third-generation CD19 CAR T-cells (CARTs), enabled the cells to overcome the resistance to CARTs. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.